Improvement of Obesity-Related Comorbidities After Bariatric Procedures: A Network Meta-Analysis of Endoscopic Versus Surgical Interventions.

Authors

Noppachai Siranart, Panisara Fangsaard, Patavee Pajareya, Daniel Martin Simadibrata, Peenaprapa Tangpradubkiat, Somkiat Phutinart, Yanisa Chumpangern, Tanattida Kassels, Sireenada Sattawatthamrong, Premkamol Patraithikul, Kittithat Tantitanawat

Published in

Digestive diseases and sciences. Jul 09, 2026. Epub Jul 09, 2026.

Abstract

Recent advances in bariatric interventions have introduced innovative surgical and endoscopic techniques aimed at promoting weight loss and improving obesity-related comorbidities. This study compares the effectiveness of various bariatric procedures in managing metabolic conditions and optimizing clinical outcomes.
A systematic literature search through January 2025 identified comparative studies, including 16 randomized controlled trials (RCTs) and 39 observational studies (follow-up range: 6-120 months), evaluating diabetes mellitus (DM), hypertension (HTN), dyslipidemia (DLP), and obstructive sleep apnea (OSA) outcomes following bariatric surgery. Secondary outcomes included de novo gastroesophageal reflux disease (GERD) incidence and GERD improvement.
Fifty-five studies involving 61,154 patients were analyzed. For DM improvement, one-anastomosis gastric bypass (OAGB) was significantly superior to both Roux-en-Y gastric bypass (RYGB) (OR: 1.92; 95% CI: 1.18-3.13) and sleeve gastrectomy (SG) (OR: 2.47; 95% CI: 1.49-4.09). OAGB and RYGB also showed significantly greater HTN improvement compared to SG (OR: 1.84; 95% CI: 1.20-2.84 and OR: 1.30; 95% CI: 1.14-1.49, respectively). For de novo GERD, ESG (OR: 0.08; 95% CI: 0.01-0.72) and RYGB (OR: 0.29; 95% CI: 0.18-0.48) showed significantly lower odds than SG. For GERD improvement, OAGB (OR: 5.48; 95% CI: 1.52-19.76) and RYGB (OR: 3.82; 95% CI: 2.09-6.97) significantly outperformed SG. P-score rankings placed SADI highest for DM (0.932), OAGB for HTN (0.769) and DLP (0.731), and SASI for both de novo GERD (0.803) and GERD improvement (0.900).
OAGB, SASI, SADI, and ESG demonstrate superior efficacy in improving obesity-related comorbidities and GERD outcomes, supporting their consideration as leading options in individualized bariatric care. However, evidence is limited with outcomes heterogenously defined across studies. Future RCTs are needed to provide comparative efficacy between these interventions.

PMID:
42423932
Bibliographic data and abstract were imported from PubMed on 09 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.